Neoadjuvant RC48 Plus Carboplatin for HER2-expressing Advanced Ovarian Cancer

Summary

The goal of this phase II single arm prospective clinical study is to evaluate the efficacy and toxicity of RC48 plus carboplatin neoadjuvant therapy in HER2 expressed epithelial ovarian cancer patients. The main questions it aims to answer are: * The improvement of complete resection rate and pathological complete rate of this regimen. * The delayed effect of treatment regimens on patient's recurrence.

Timeline

Start

2024-09-01

Primary completion

2025-09-01

Completion

2026-09-01

Drugs

Indications